Method and compositions for enhancing immunotherapeutic treatment of a cancer
OwnerDavid H. Munninventor
Life of this patent
Estimating the term…
Abstract
Provided are methods and compositions for enhancing treatment of a cancer by administering a therapeutic agent for the treatment of a cancer together with a second agent that elevates the level of protein p53. The second agent generates in the tumor a population of dendritic cells expressing at least one of Batf3, IRF5, CD103, and XCR1. The second therapeutic agent can also suppress an autoimmune response to non-cancerous tissue in the patient if generated by an immunotherapeutic agent. The method can further comprise administering a PTEN phosphatase inhibitor.
Claims31
A method for enhancing a therapeutic treatment of a cancer, said method comprising the steps of:
- (a) administering to a patient in need thereof a therapeutic dose of a first therapeutic agent for the treatment of a cancer in said patient;
- and
- (b) administering to the patient a therapeutic dose of a second therapeutic agent that elevates the level of protein p53 in said patient.
A composition comprising a first therapeutic agent for the treatment of a cancer in a recipient patient and a second therapeutic agent that elevates the level of protein p53 in said patient.
A composition comprising an immunotherapeutic agent effective in generating an immune response directed against a tumor in a recipient patient, a therapeutic agent that elevates the level of protein p53 in a recipient patient, wherein said therapeutic agent is nutlin-3a, and a pharmaceutically acceptable carrier.
A kit comprising an first therapeutic agent directed against a tumor in a recipient patient, a second therapeutic agent that elevates the level of protein p53 in a recipient patient, and a pharmaceutically acceptable carrier, wherein the first therapeutic agent, the second therapeutic agent, and the pharmaceutically acceptable carrier are packaged individually or in any combination, and instructions for the use of the packaged agents and carrier to prepare an effective dose of each agent for administration individually or in combination to a patient in need thereof.
Dependencies are inferred from the claim text.